Table 4.

Clinical trials of MV-NIS

Therapeutic agent	Cancer type	Phase, study type	Mode of therapy	Purpose of the study	Status	Clinical trial number
MV-NIS	Ovarian, fallopian or peritoneal cancer	Phase 2, open-label, randomized parallel study	Intra-peritoneal administration of MV-NIS and intravenous administration of the drugs like paclitaxel or gemcitabine	Safety, tolerability and efficacy evaluation of MV-NIS in comparison with standard chemotherapy	Recruiting	NCT02364713
MV-NIS in combination with cyclophosphamide	Recurrent or refractory multiple myeloma	Phase 1 and phase 2, open-label, non-randomized, parallel study	Intravenous administration of MV-NIS with cyclophosphamide	Determination of maximum tolerated dose of MV-NIS in combination with cyclophosphamide	Active, not recruiting	NCT00450814
MV-NIS in combination with cyclophosphamide	Recurrent or refractory multiple myeloma	Phase 2 open-label single-group assignment	Intravenous administration of MV-NIS	Determination of the clinical efficacy of MV-NIS in combination therapy with cyclophosphamide	Recruiting	NCT02192775
MV-NIS	Malignant pleural mesothelioma	Phase 1, open-label, single-group study	Intra-pleural administration of the oncolytic virus	Dose determination and safety evaluation	Active, not recruiting	NCT01503177
MV-NIS	Head and Neck metastatic squamous cell carcinoma or metastatic breast cancer	Phase1, open-label, single-group study	Intra-tumoral administration of MV-NIS	Dose determination and safety evaluation	Suspended	NCT01846091
MV-NIS	Unresectable or recurrent malignant peripheral nerve sheath tumor	Phase 1, single-group, open-label study	Intra-tumoral administration of MV-NIS	Dose determination and safety evaluation	Recruiting	NCT02706230